Are Oral Bisphosphonates Effective in Improving Lumbar Bone Mineral Density in Breast Cancer Survivors With Osteopenia or Osteoporosis

摘要: Abstract Objective: Breast cancer survivors with osteoporosis or osteopenia are commonly encountered in primary care and gynaecology Practices. Our objective was to determine whether treatment oral bisphosphonates (alendronate cyclic etidronate) more effective than calcium vitamin D improving lumbar spine bone mineral density BMD within one year breast survivors. Methods: at least of clinical follow-up were identified from the prospective observational Canadian Database Osteoporosis Osteopenia (CANDOO). Analysis covariance used examine effects bisphosphonate therapy on change compared (analysis adjusted for baseline L2–L4 BMD, current tamoxifen use, number prevalent vertebral fractures [VFs], time since diagnosis cancer, age). Results: Eighteen patients took D, 25 etidronate, 27 alendronate. Adjusted one-Year increases alendronate etidronate as follows: 4.53% 95% confidence interval CI 1.26%, 7.81 %, P = 0.008), 1.85% (−1.55%, 5.25%, 0.280). significantly greater VF those without ( 0.025). In contrast, associated a decrease 0.002. We unable detect any effect age changes year. Conclusion: Treatment improvements when D.